Koshinski Asset Management
ITRM

Koshinski Asset Management’s Iterum Therapeutics ITRM Stock Holding History

Koshinski Asset Management’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-333
Closed -$1.77K – 1295
2022
Q1 		$1.77K Hold
333
– – ﹤0.01% 1997
2021
Q4 		$1.96K Hold
333
– – ﹤0.01% 1998
2021
Q3 		$2.79K Buy
+333
New +$4.1K ﹤0.01% 1963

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

Koshinski Asset Management's ITRM Position: Q2 2022 in Review

Koshinski Asset Management sold out of Iterum Therapeutics (ITRM) in Q2 2022, closing a stake of 333 shares — an estimated $1.77K sold.

Koshinski Asset Management first reported a position in ITRM in Q3 2021 and held it in 3 quarters. The position peaked at $2.79K in Q3 2021. 38 funds tracked by Wall St. Rank hold ITRM as of Q2 2022.

  • Koshinski Asset Management reported no remaining Iterum Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Koshinski Asset Management sold 333 Iterum Therapeutics shares in Q2 2022, an estimated $1.77K.
  • Koshinski Asset Management first reported a position in Iterum Therapeutics in Q3 2021 and held it in 3 quarters.
  • Koshinski Asset Management's Iterum Therapeutics position peaked at $2.79K in Q3 2021.
  • 38 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2022.

Based on Koshinski Asset Management's 13F filing for Q2 2022, filed 12 Jul 2022.